Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Inclusion criteria:

1. T2DM patients and healthy controls aged =18 to <70 at Visit 1.

2. Patients diagnosed with T2DM according to the American Diabetes Association criteria
prior to informed consent who are drug-naïve

3. T2DM patients on a stable dose of allowed concomitant medications (as determined by
investigator) for 30 days prior to entering the study.

4. T2DM patients with HbA1c between >7 and <10.0% (>53 mmol/mol and <86 mmol/mol) at
Visit

Exclusion criteria:

1. Patients with type 1 diabetes mellitus.

2. Patients with uncontrolled hyperglycemia with a fasting plasma glucose level greater
than 240 mg/dl after an overnight fast.

3. Patients with a history of clinically significant heart disease (New York Heart
Classification greater than class 3; more than non-specific ST-T wave changes on the
ECG), peripheral vascular disease (history of claudication), or pulmonary disease as
determined by investigator.

4. Medical history of cancer (except for basal cell carcinoma) and/or treatment for
cancer within the last 5 years.